KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Free Cash Flow (2016 - 2025)

Novavax (NVAX) has 16 years of Free Cash Flow data on record, last reported at -$36.0 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 79.17% year-over-year to -$36.0 million; the TTM value through Dec 2025 reached -$244.6 million, down 176.93%, while the annual FY2025 figure was -$244.6 million, 176.93% down from the prior year.
  • Free Cash Flow reached -$36.0 million in Q4 2025 per NVAX's latest filing, down from $104.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $649.3 million in Q1 2021 and bottomed at -$337.5 million in Q4 2021.
  • Average Free Cash Flow over 5 years is -$57.7 million, with a median of -$108.0 million recorded in 2022.
  • The widest YoY moves for Free Cash Flow: up 2894.51% in 2021, down 1299.28% in 2021.
  • A 5-year view of Free Cash Flow shows it stood at -$337.5 million in 2021, then soared by 83.49% to -$55.7 million in 2022, then plummeted by 227.19% to -$182.3 million in 2023, then increased by 5.3% to -$172.6 million in 2024, then skyrocketed by 79.17% to -$36.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$36.0 million in Q4 2025, $104.4 million in Q3 2025, and -$127.5 million in Q2 2025.